AssessmentExecutive Assessment
 
       
Executive Team
 

Iyabode Akinsanya-Beysolow,
MD, MPH


Paul G. Auwaerter,
MD, MBA, FACP, FIDSA

John G. Bartlett,
MD

Todd T. Brown,
MD, Phd


Michael A. Chattergoon,
MD, PhD


Joseph Cofrancesco Jr.,
MD, MPH, FACP


Calvin J. Cohen,
MD, MSc


Sara E. Cosgrove,
MD, MS


Thomas Donner,
MD, (planning committee)


Joel E. Gallant,
MD, MPH


Amita Gupta,
MD, MHS


Lawrence Herman,
MPA, RPA-C, DFAAPA


Charles Hicks,
MD


Christopher Hoffmann,
MD, MPH


Rita Rastogi Kalyani,
MD, MHS


Rebecca A. Kazin,
MD


Gregory M. Lucas,
MD, PhD


David H. Madoff,
MD, PhD


Kieren A. Marr,
MD


Nisa M. Maruthur,
MD, MHS


Nestoras Mathioudakis,
MD


Michael Melia,
MD


Dionissios Neofytos,
MD, MPH


Eric Nuermberger,
MD


Kathleen R. Page,
MD


Trish M. Perl,
MD, MSc


Paul A. Pham,
PharmD


Richard E. Rothman,
MD, PhD, FACEP


Paul E. Sax,
MD


Mark S. Sulkowski,
MD


Aimee K. Zaas,
MD, MHS





 

Title: "Optimizing Patient Outcomes: Sequencing Therapy in Type 2 Diabetes Part 2: Managing Persistent Hyperglycemia”

Presented by: The Johns Hopkins University School of Medicine

Release Date: July 25, 2013
Expiration Date: July 25, 2014

Estimated time to complete each part of this activity:
30 minutes for each of the three activities. Each part of this activity has been approved for a maximum of 0.50 AMA PRA Category 1 Credit(TM). There are no fees or prerequisites.

Acknowledgement of Commercial Support: Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc., which was made possible, in part, through a collaboration with Eli Lilly and Company.